Abstract 5965: Plk1-BRN2 signaling axis drives lineage plasticity in castration-resistant prostate cancer

Abstract Prostate cancer frequently acquires resistance to androgen receptor (AR)-targeted therapies through lineage plasticity, leading to neuroendocrine prostate cancer (NEPC), an aggressive and therapy-resistant subtype. BRN2 (POU3F2) is a key transcription factor that drives this transition and is normally repressed by AR signaling; however, the upstream mechanisms that activate BRN2 during therapy resistance remain poorly defined. We identify Polo-like kinase 1 (Plk1), a mitotic kinase upregulated in advanced disease, as a previously unrecognized upstream regulator of BRN2. Plk1 directly phosphorylates BRN2 at a conserved motif, enhancing its transcriptional activity and promoting downstream neuroendocrine reprogramming. Disruption of this phosphorylation markedly diminishes neuroendocrine marker expression and inhibits cellular plasticity. RNA-seq analysis further revealed suppression of EMT-associated transcriptional programs as a major downstream consequence of impaired BRN2 phosphorylation. In vivo, using a robust NEPC mouse model, inhibition of Plk1-dependent BRN2 activation reprograms tumor histology and molecular phenotype toward an AR-positive prostate adenocarcinoma (ARPC) state, indicating inhibition of lineage plasticity. These findings identify Plk1-mediated BRN2 phosphorylation as a critical driver of neuroendocrine transdifferentiation and highlight the Plk1-BRN2 axis as a promising therapeutic target to prevent NEPC progression in castration-resistant prostate cancer. Citation Format: Fatemeh Seilani, Meng Wu, Jia Peng, Mohammad Esfini Farahani, Xinyi Wang, Jinghui Liu, Yanquan Zhang, Ruixin Wang, Xiaoqi Liu. Plk1-BRN2 signaling axis drives lineage plasticity in castration-resistant prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5965.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-5965
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 5965: Plk1-BRN2 signaling axis drives lineage plasticity in castration-resistant prostate cancer

Meng Wu, X. Liu, Mohammad Esfini Farahani, Xinyi Wang et al.
Cancer Research
Prostate Cancer Treatment and Research
article

Abstract 5965: Plk1-BRN2 signaling axis drives lineage plasticity in castration-resistant prostate cancer

Meng Wu, X. Liu, Mohammad Esfini Farahani, Xinyi Wang, Jia Peng, Jinghui Liu, Fatemeh Seilani, Yanquan Zhang, Ruixin Wang
article en

Abstract

Abstract Prostate cancer frequently acquires resistance to androgen receptor (AR)-targeted therapies through lineage plasticity, leading to neuroendocrine prostate cancer (NEPC), an aggressive and therapy-resistant subtype. BRN2 (POU3F2) is a key transcription factor that drives this transition and is normally repressed by AR signaling; however, the upstream mechanisms that activate BRN2 during therapy resistance remain poorly defined. We identify Polo-like kinase 1 (Plk1), a mitotic kinase upregulated in advanced disease, as a previously unrecognized upstream regulator of BRN2. Plk1 directly phosphorylates BRN2 at a conserved motif, enhancing its transcriptional activity and promoting downstream neuroendocrine reprogramming. Disruption of this phosphorylation markedly diminishes neuroendocrine marker expression and inhibits cellular plasticity. RNA-seq analysis further revealed suppression of EMT-associated transcriptional programs as a major downstream consequence of impaired BRN2 phosphorylation. In vivo, using a robust NEPC mouse model, inhibition of Plk1-dependent BRN2 activation reprograms tumor histology and molecular phenotype toward an AR-positive prostate adenocarcinoma (ARPC) state, indicating inhibition of lineage plasticity. These findings identify Plk1-mediated BRN2 phosphorylation as a critical driver of neuroendocrine transdifferentiation and highlight the Plk1-BRN2 axis as a promising therapeutic target to prevent NEPC progression in castration-resistant prostate cancer. Citation Format: Fatemeh Seilani, Meng Wu, Jia Peng, Mohammad Esfini Farahani, Xinyi Wang, Jinghui Liu, Yanquan Zhang, Ruixin Wang, Xiaoqi Liu. Plk1-BRN2 signaling axis drives lineage plasticity in castration-resistant prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5965.

Cancer ResearchVol. 86(7_Supplement)
University of Kentucky (US)
Good health and well-being
Openalex Percentile: Top 5%
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.